Enzyvant and Altavant announce merger to accelerate rare disease ...
Dec 8, 2022 · Enzyvant Therapeutics (Enzyvant) and Altavant Sciences (Altavant) have announced a merger to form a biopharmaceutical company focused on accelerating the development of therapies for patients with rare diseases. The combined company, which retains the name Enzyvant, will have a full range of capabilities required to advance ‘bold science ...
PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
Novo Nordisk and Ascendis enter $285m partnership for once-monthly GLP-1 drug. GSK expands immunology pipeline by acquiring Chimagen’s CMG1A46 in deal worth $850m. AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition. Merck acquires oncology spinout Modifi Biosciences in deal worth $1.3bn.
About T40 - PMLiVE
The aim of the T40 listing is to highlight those creative agencies having the most impact in the UK healthcare sector in 2023. The agencies were drawn from a shortlist based on selected 2023 healthcare awards schemes and specialist advertising, branding, creative and design agencies drawn from a number of sources including PMLiVE’s PMHub ...
Top 40 overall - PMLiVE
21. Dice Medical Communications. 25-49 staff. 25-49 staff. Between 10 and 15 years. Dice is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We …
Johnson & Johnson receives updated NICE recommendation for …
Oct 14, 2024 · Johnson & Johnson’s (J&J) Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat relapsed and refractory multiple myeloma (RRMM) in adults. The final draft guidance applies to RRMM patients in England and Wales who have received at least three lines of therapy, including an ...
Moderna shares positive phase 3 results for mRNA influenza …
Sep 15, 2023 · Moderna has shared positive results from a late-stage trial of its influenza vaccine, with mRNA-1010 shown to generate a stronger immune response against all four World Health Organization (WHO)-recommended flu strains compared to GSK’s Fluarix. Improved immunogenicity was observed across age groups, including older adults, and the company ...
SMC approves Yescarta and Keytruda, rejects Perjeta - PMLiVE
Oct 8, 2019 · SMC approves Yescarta and Keytruda, rejects Perjeta. Gilead’s Yescarta and Merck/MSD’s Keytruda have been accepted by the Scottish Medicines Consortorium for use by NHS Scotland – while Roche’s Perjeta has faced rejection from the regulatory authority. Last year, Gilead agreed a market access deal with NHS England for its groundbreaking ...
Arrowhead’s RNAi therapeutic plozasiran shows promise in familial ...
Sep 3, 2024 · Arrowhead Pharmaceuticals has announced positive results from a late-stage study of its investigational RNAi therapeutic in patients with familial chylomicronaemia syndrome (FCS), a rare genetic disorder affecting an estimated one to two per million people.
UCLA launches study of personalised cancer vaccine in ... - PMLiVE
Aug 14, 2024 · UCLA launches study of personalised cancer vaccine in paediatric brain tumours. H3 G34-mutant diffuse hemispheric gliomas are brain tumours commonly found in adolescents and young adults. UCLA Health has announced the launch of a clinical trial to tackle aggressive brain tumours in adolescents and young adults using a personalised cancer vaccine.
GSK receives CHMP recommendation for meningococcal disease …
Oct 3, 2024 · GSK has received a recommendation from the European Medicines Agency’s human medicines committee for a single-vial, fully liquid presentation of its meningococcal vaccine Menveo. The new presentation, which would be indicated for use in individuals aged two years and older, would offer healthcare providers an option that does not require ...